Last reviewed · How we verify

CETUXIMAB — Competitive Intelligence Brief

CETUXIMAB (CETUXIMAB) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Epidermal Growth Factor Receptor Antagonist [EPC].

marketed Epidermal Growth Factor Receptor Antagonist [EPC] Monoclonal antibody Live · refreshed every 30 min

Target snapshot

CETUXIMAB (CETUXIMAB).

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
CETUXIMAB TARGET CETUXIMAB marketed Epidermal Growth Factor Receptor Antagonist [EPC] 2004-01-01
Portrazza NECITUMUMAB Eli Lilly Co marketed Epidermal Growth Factor Receptor Antagonist [EPC] Epidermal growth factor receptor 2015-01-01
Erbitux cetuximab Imclone marketed Epidermal Growth Factor Receptor Antagonist [EPC] Epidermal growth factor receptor 2004-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Epidermal Growth Factor Receptor Antagonist [EPC] class)

  1. · 1 drug in this class
  2. Eli Lilly Co · 1 drug in this class
  3. Imclone · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CETUXIMAB — Competitive Intelligence Brief. https://druglandscape.com/ci/chembl-chembl1201577. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: